A prospective double-blind randomized phase I clinical trial of BRII-778 for HIV-infections in healthy adults subjects
Latest Information Update: 01 Feb 2023
At a glance
- Drugs BRII 778 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 19 Oct 2022 Results published in the Brii Biosciences Media Release.
- 23 Aug 2022 According to Brii Biosciences media release, this trial will be presented at the IDWeek Conference in October 2022.
- 22 Mar 2022 According to Brii Biosciences media release, Phase 1 SAD/MAD data will be published at a future scientific conference in the second half of 2022.